Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...
Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply
Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...
CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine
CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...
JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC
JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...
Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials
Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...
Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang
China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...
Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng
The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...
Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial
China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its...
AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery
China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...
NHC Proposes Updates to Access Standards for Class A and B Medical Equipment
The National Healthcare Commission (NHC) has released two proposed updates to the Access Standards for...
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...
RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors
RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from...
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...
Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical...
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm...
Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors
The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co.,...
Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...
HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency
HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...